

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section, Tokyo and Osaka Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com>

**Daiichi Sankyo Launches Three New Generic Drugs Through Its
Daiichi Sankyo Espha Subsidiary**

Tokyo, Japan (June 21, 2013) – Daiichi Sankyo Company, Limited announced today that its Japan domestic generics subsidiary, Daiichi Sankyo Espha, has launched three new generic drugs with two active ingredients.

Overview

1. Product names/therapeutic categories

Product name	Therapeutic category	Original brand name
Pramipexole hydrochloride 0.125 mg tablets DSEP	Dopamine agonist for treatment of Parkinson's disease	BI • Sifrol® 0.125 mg, 0.5 mg tablets
Pramipexole hydrochloride 0.5 mg tablets DSEP		
<Product for new indication> Amlodipine 10 mg tablets DSEP	Calcium channel antagonist for treatment of hypertension and angina	Norvasc® 10 mg tablets Amlodin® 10 mg tablets

2. Product attributes (Pramipexole hydrochloride tablets)

Daiichi Sankyo Espha has created innovative labeling on tablets and PTP sheets to make them easier for patients to see and understand.

- “Pitch control” - Through pitch control on both sides of the tablet, it is possible to display the product name and dosage on each pill, making it easier for patients to recognize.
- Design that allows for easy identification - Special markings on both sides of the PTP sheets to make tablets easier to identify.
- PTP sheets also employ a material to block light while still allowing tablets to be visible.
- GS1 data barcode - In order to prevent medication errors, the GS1 data barcode is marked on each tablet.

Example: Pramipexole Hydrochloride 0.5 mg DSEP tablets and PTP sheets



About Daiichi Sankyo Espha

Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and accommodate rising demand based on the spirit of the Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

Daiichi Sankyo Espha Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshiwaka

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo

*Daiichi Sankyo Group corporate philosophy

To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs